The U.S. Food and Drug Administration has approved a new drug called Cellcept (mycophenolate mofetil) to help prevent organ rejection in patients who have had a kidney, heart, or liver transplant. Organ rejection happens when the body's immune system attacks the new organ. Cellcept works by calming the immune system so it is less likely to attack the transplanted organ. It is meant to be used along with other immunosuppressant medicines, not alone.
Cellcept is approved for adults and children aged 3 months and older. It comes in both oral (taken by mouth) and intravenous (given through a vein) forms. This flexibility allows doctors to choose the best way to give the medicine, especially right after the transplant surgery when patients may not be able to swallow pills.
The approval is based on clinical studies that showed Cellcept reduced the number of rejection episodes in these transplant patients. For patients, this means there is another tool to help keep their new organ healthy. However, it is important to remember that every patient is different, and what works for one person may not work for another.
If you or a loved one is a transplant recipient, talk to your doctor about whether Cellcept might be a good option. Your doctor can explain the benefits and risks, and help you decide on the best treatment plan. This approval does not mean that Cellcept is right for everyone, and it does not replace the need for regular check-ups and monitoring after a transplant.
